The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key updates in the report were highlighted in a presentation by Claus F ...
In conclusion, COPD is a global disease, with increasing prevalence and health-related impact. The loss of FEV 1 may be slowing down, but what is really needed is an intervention that improves it in ...
Chronic obstructive pulmonary disease (COPD) affects approximately 29 million people in the U.S. and is the fourth leading cause of death. Mucus plugging (mucus that accumulates in the lungs and ...
COPD experimental therapy 9MW1911 reduced moderate to severe exacerbations in a Phase 2a trial, showing a favorable safety ...
Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE ...
Emphysema is a chronic lung condition characterised by the destruction of alveolar walls. This pathophysiology involves damage that impairs the lungs' ability to recoil: decreasing airflow and causing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback